Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 10/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3073195 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CYP3A4MAPTCYP2C9HPGD | |
| SCHEMBL3078902 | 0.80 | ALDH1A1 (0.36) | ALDH1A1CYP3A4MAPTCYP2C9HPGD | |
| SCHEMBL3078907 | 0.80 | ALDH1A1 (0.36) | ALDH1A1CYP3A4MAPTCYP2C9HPGD | |
| SCHEMBL3080913 | 0.80 | ALDH1A1 (0.36) | ALDH1A1CYP3A4MAPTCYP2C9HPGD | |
| SCHEMBL3080910 | 0.80 | ALDH1A1 (0.36) | ALDH1A1CYP3A4MAPTCYP2C9HPGD | |
| SCHEMBL3076151 | 0.80 | ALDH1A1 (0.34) | ALDH1A1CYP3A4MAPTCYP2C9HPGD | |
| SCHEMBL3076155 | 0.80 | ALDH1A1 (0.34) | ALDH1A1CYP3A4MAPTCYP2C9HPGD | |
| SCHEMBL3078460 | 0.78 | ALDH1A1 (0.38) | ALDH1A1CYP3A4MAPTCYP2C9HPGD | |
| SCHEMBL3078458 | 0.78 | ALDH1A1 (0.38) | ALDH1A1CYP3A4MAPTCYP2C9HPGD | |
| SCHEMBL3080367 | 0.76 | HPGD (0.39) | ALDH1A1CYP3A4MAPTCYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790882-B2 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick M. (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick (CH) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | C1R, ARL1, C5 | ALDH1A1 2507/4885CYP3A4 264/4885MAPT 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.